

Glaucoma is a complex disease, and currently the only way to maintain patient health is by lowering intraocular pressure. Gene therapy to treat the disease is rapidly evolving. This is a much needed area of glaucoma treatment that can be applied to a variety of glaucoma types.

A major risk factor for glaucoma is high IOP and causes blindness primarily due to RGC damage and death. Therefore, Ace Ophthalmology provides gene therapy development services for glaucoma, targeting candidate genes related to IOP and RGC, as well as many other related genes and pathways.